Mitofusin-2 mediates doxorubicin sensitivity and acute resistance in Jurkat leukemia cells

Carl W. Decker a, Jerome Garcia c, Kristelle Gatchalian a, Deronisha Arceneaux d, Clarice Choi a, Derick Han b, Jeniffer B. Hernandez b,*,

a Keck Graduate Institute, Henry E. Riggs School of Applied Life Sciences, 535 Watson Drive, Claremont, CA, 91711, USA
b Keck Graduate Institute, Department of Pharmaceutical Sciences, School of Pharmacy and Health Sciences, 535 Watson Drive, Claremont, CA, 91711, USA
c University of La Verne, Department of Biology, 1950 3rd Street, La Verne, CA, 91750, USA
d Pitzer College, 1050 N Mills Ave, Claremont, CA, 91711, USA

ARTICLE INFO

Keywords:
Mitochondrial fusion
Doxorubicin
MFN-2
Sensitivity
OXPHOS

ABSTRACT

Mitochondria oscillate along a morphological continuum from fragmented individual units to hyperfused tubular networks. Their position at the juncture of catabolic and anabolic metabolism couples this morphological plasticity, called mitochondrial dynamics, to larger cellular metabolic programs, which in turn implicate mitochondrial fusion in a number of disease states. In many cancers, fragmented mitochondria engage the cell with the biosynthetic capacity of aerobic glycolysis in service of proliferation and progression. Chemo-resistant cancers, however, favor remodeling dynamics that yield fused mitochondrial assemblies utilizing oxidative phosphorylation (OXPHOS) through the electron transport chain (ETC). In this study, expression of Mitofusin-2 (MFN-2), a GTPase protein mediator of mitochondrial fusion, was found to closely correlate to Jurkat leukemia cell survival post doxorubicin (DxR) assault. Moreover, this was accompanied by dramatically increased expression of OXPHOS respiratory complexes and ATP Synthase, as well as a commensurate escalation of state III respiration and respiratory control ratio (RCR). Importantly, CRISPR knockout of MFN-2 resulted in a considerable decrease of doxorubicin (DxR) median lethal dose compared to a treated wildtype control, suggesting an important role of mitochondrial fusion in chemotherapy sensitivity and acute resistance.

1. Introduction

T-cell leukemias are a group of blood cancers that are among the most common in the world, affecting over 2.3 million people globally and causing 353,000 deaths annually [1,2]. Notably, leukemia is the most common pediatric cancer [3]. Standard of care treatments routinely incorporate the CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone) chemotherapy regimen [4], which includes the intercalating anthracycline doxorubicin (DxR). While useful in treating early-to mid-stage lymphomas [5], sustained DxR-inclusive CHOP also presents significant side effects to patients, including dilated cardiomyopathy, congestive heart failure, and death. Moreover, cancerous cells exposed to repeated dosing of chemotherapy regimens, as well as those that are recurrent, are frequently less primed to undergo mitochondria-mediated intrinsic apoptosis [6], making them less sensitive to additional applications of chemotherapy. This is significant, as lymphoblastic leukemias have a relapse rate of 10–25% in children [7,8], for which prognoses are dramatically impacted [9]. As such, mitochondrial action in leukemia cells under chemotherapeutic assault serves as a potentially crucial area in which to research drug sensitivity and efficacy.

Mitochondria are active, double-membrane bound hubs of bioenergetics, cell signaling, and redox balance that fluctuate along a spectrum of fused superstructures to smaller, fragmented organelles. Importantly, these morphological changes-together called mitochondrial dynamics—are closely connected to larger metabolic schemes. Specifically, fission has been shown to favor glycolysis [10], while several studies have linked fusion with induction of oxidative phosphorylation/OXPHOS [11–14], and are mediated by the action of a family of intracellular GTPase proteins. For example, the GTPase dynamin related protein (DRP-1), when phosphorylated at serine616, localizes with Mitochondrial Fission Factor (Mff) at the outer mitochondrial membrane (OMM), dividing targeted mitochondria at scission sites to induce a fragmented network morphology and a switch to
glycolytic metabolism. Conversely, the mitofusin proteins (MFN-1,2) function to merge the mitochondrial outer membrane (MOM) of fusing mitochondria. The relative balance of these proteins and their subsequent action are essential to normal cell physiology, and their dysregulation has been connected to a number of cancers [15]. Conversely, mitochondrial fusion has been shown to inhibit migration in breast cancer, establishing a linking mechanism between cancer invasiveness and mitochondrial dynamics [16]. Unfortunately, many similar links between mitochondrial dynamics and cell sensitivity to chemotherapy remain unexplored or poorly characterized.

The present study aimed to address this dearth by examining the effects of doxorubicin on the mitochondrial dynamics in leukemia Jurkat cells, with particular attention paid to mitochondrial phenotype and respiratory capacity in cells surviving chemotherapeutic assault. We also sought to characterize the relationship between those mitochondrial dynamics and cellular sensitivity to chemotherapy remain unexplored or poorly characterized.

The present study aimed to address this dearth by examining the effects of doxorubicin on the mitochondrial dynamics in leukemia Jurkat cells, with particular attention paid to mitochondrial phenotype and respiratory capacity in cells surviving chemotherapeutic assault. We also sought to characterize the relationship between those mitochondrial dynamics and cellular sensitivity to chemotherapy remain unexplored or poorly characterized.

2. Materials and methods

2.1. Cell culture and chemotherapy application

Jurkat peripheral blood t-lymphocytes from ATCC (TIB-152™) were grown in RPMI medium supplemented with 2 mm glutamine, 10% fetal bovine serum, and penicillin/streptomycin (50 μM mL⁻¹), all from ThermoFisher/Gibco (Waltham, Massachusetts), in a humidified atmosphere containing 5% CO₂/95% air at 37 °C.

2.2. Cell viability

To separate live cells, suspension was spun down at 118 × g on an Eppendorf 5702R centrifuge with a 13.2 cm radius (Eppendorf rotor A-4-38). For trypan exclusion, a 0.4% trypan solution (SigmaAldrich, St. Louis, Missouri) was applied to fresh cell suspension in a 1:1 ratio. Flow cytometry was performed per the protocol in prior studies [17].

2.3. Mfn-2 knockout CRISPR vector transfection

Mfn2 CRISPR/Cas9 KO Plasmid was obtained from Santa Cruz Biotechnology (Santa Cruz, California), mixed in proportion with SCBT UltraCruz Transfection Reagent (Santa Cruz, California) and OPTI-MEM Reduced Serum Media (ThermoFisher, Waltham, Massachusetts), and applied to cells in-vitro for 72 h, mixing suspension every 12 h.

2.4. Immunoblotting

Western blot was conducted as per our previous work [18]. Aliquots of cytoplasmic or mitochondrial extracts were fractionated by electrophoresis on 8–12% SDS polyacrylamide gels (BioRad, Hercules, CA). Subsequently, proteins were transferred to PVDF membranes and blots were blocked with 1% casein (w/v) nonfat milk dissolved in Tris-buffered saline (TBS) with Tween-20 (BioRad, Hercules, CA). Total OXPHOS cocktail, DRP-1, pDRP-1, and MFN-2 primary antibodies were obtained from Abcam (Cambridge, UK). All blots shown are representative samples from 3 to 7 experiments.

2.5. Real-time quantitative PCR

RT-qPCR was performed via our previous work [19]. Total RNA was extracted from treated cells through liquid phase separation via use of
A.

![Graph A](image1.png)

**T = 1 Hour**

- UT Ctrl
- DXR (0.5 μM)
- DXR (0.75 μM)
- DXR (1 μM)

**T = 24 Hours**

- UT Ctrl
- DXR (0.5 μM)
- DXR (0.75 μM)
- DXR (1 μM)

B.

![Graph B](image2.png)

**pDRP-1**

- pDRP-1 (0.5 μM)
- pDRP-1 (0.75 μM)
- pDRP-1 (1 μM)

**pMFN-2**

- pMFN-2 (0.5 μM)
- pMFN-2 (0.75 μM)
- pMFN-2 (1 μM)

**β-actin**

- β-actin (0.5 μM)
- β-actin (0.75 μM)
- β-actin (1 μM)

**MFN-2**

- MFN-2 (0.5 μM)
- MFN-2 (0.75 μM)
- MFN-2 (1 μM)

**PHB-1**

- PHB-1 (0.5 μM)
- PHB-1 (0.75 μM)
- PHB-1 (1 μM)

**Actin**

- Actin (0.5 μM)
- Actin (0.75 μM)
- Actin (1 μM)

Fig. 2. A) Real-time quantitative PCR gene detection comparison measuring protein mediators of mitochondrial morphology across doxorubicin (DxR) treatment concentrations and untreated control (UT) at 1 and 24 h relative to an 18S control gene. At 1 h post-DxR treatment, transcript of dynamin related protein 1 (DRP-1), a GTPase mediator of mitochondrial fission, is shown to decrease. This is accompanied by a concurrent increase of MFN-2, a mitochondrial outer membrane fusion mediator, indicating hasty mitochondrial fusion in response to DxR; these same dynamics are observed at a 24 h endpoint. B) Immunoblot and densitometry (relative arbitrary units, AU) of mitochondrial dynamics mediators in DxR treated t-cells at 24 h. Corroborating RT-qPCR data, both DRP-1 and activated pDRP-1 are decreased in response to treatment. MFN-2 is likewise shown to increase as in RT-qPCR assay, though an increase of MFN-1 was determined to be statistically insignificant. Prohibitin 1 (PHB-1), a pleiotropic scaffolding protein known to stabilize mitochondrial inner membrane proteins and support cristae morphogenesis and maintenance, is upregulated in treated conditions compared to control. Taken together, data suggest MFN-2 mediated fusion in response to DxR, beginning at the latest 1 h after treatment, through to a 24 h interval. Data represent the mean ± SD, n > 3.

TriPure reagent (Roche Diagnostics, Indianapolis, IN, USA), chloroform, and 2 Propanol. The resulting RNA was resuspended in RNase-free water and quantified using NanoQuant Infinite 200 Pro. For the qPCR, approximately 100 ng of cDNA template per treatment condition was mixed with 1× AzuraQuant Green Fast qPCR Mix HiRox (Azura Genomics, Massachusetts, USA), 400 nM Forward Primers (MFN2 and DRP1), 400 nM Reverse Primers (MFN2 and DRP1), and RNase free water. 18S was also amplified as an internal control. Samples were then loaded into a 96 well plate at 20 μL total volume per well with each condition run as triplicates. A Roche Lightcycler 96 was set for 1 cycle at 95 °C for 2 min, two-step amplification for 1 Cycle at 95 °C for 5 s then 40 cycles of 60 °C for 25 s, and 1 cycle at 37 °C for 30 s. The resulting Cq data was normalized with the 18S control to limit variability. The data was then analyzed using the 2^{-}\Delta\Delta CT method. All data was quantified using the Roche Lightcycler 2.0 software.

2.6. Mitochondrial respiration measurements

Respiration was measured in freshly isolated mitochondria according to our prior work [20] by monitoring oxygen consumption with a Clark-type electrode (Hanstech, UK) in respiration buffer containing 230 mM mannitol, 70 mM sucrose, 30 mM Tris–HCl, 5 mM KH2PO4, 1 mM EDTA, pH 7.4 [9]. Control and treated Jurkat suspensions with digitonin applied were added to 1 mL of respiration buffer and oxygen consumption monitored in the presence of mitochondrial Complex I substrates (glutamate/malate 7.5 mM) with or without ADP (250 μM). State IV respiration is defined as respiration in the presence of both substrates plus ADP. The RCR is defined as state III/state IV.

2.7. Statistical analysis

Statistical analyses were performed using the Student’s t-test for unpaired data and ANOVA for multiple sets. P ≤ 0.05 was defined as statistically significant.

3. Results

3.1. DxR cytotoxicity

Titration of 24-h DxR treatments established the median lethal dose for a Jurkat t-cell culture. A trypan exclusion assay and statistical analysis showed cytotoxicity in a dose-dependent relationship. 0.75 μM DxR was found to reduce cell viability by approximately half (53% of control, ± 6.6), with 0.5 μM and 1.0 μM constituting low (65% of control, ± 5.3 reduction) and high (38% of control, ± 11.3 reduction) dosing states (Fig. 1A). For validation, cell cycle analysis using 0.75 μM DxR corroborated its median dose cytotoxicity, increasing the DNA fragmentation subpopulation (indicative of apoptosis) of treated Jurkats to 52.3% ± 6.4, while reducing the proportion of cells in the proliferative G2/M phase to 4.5% ± 0.9, down from 12.1% ± 0.5 in the untreated control (Fig. 1B).

3.2. DxR induces changes to mitochondrial remodeling, including MFN-2 mediated mitochondrial fusion

Versus control, DxR treatment across low (0.25 μM), medium (0.50 μM), and high (1.0 μM) concentrations induced rapid transcription of fusion mediating MFN-2 beginning at 1hr and continuing through 24-h
molecule of glucose. Data are representative of n with doxorubicin (DxR) treatment concentration in a dose dependent manner. Data represent the mean commensurate increase in glutamate/malate-driven state III respiration. State IV respiration, or minimal respiratory capacity, is only marginally altered, suggesting (succinate dehydrogenase) is not increased, perhaps to further produce ATP through glutamate/malate-driven respiration via complex I, which is more efficient per (serine production of DRP-1, both in its total pool and activated phosphorylated ( Fig. 2 B). Western immunoblot revealed expression of MFN-2, which forms ring structures at the mitochondria inner membrane to support fusion morphology and OXPHOS, increased with DxR concentration, suggesting inner membrane fusion maintenance. Conversely, production of DRP-1, both in its total pool and activated phosphorylated (serine<sub>616</sub>) forms, was found to be inversely correlated to DxR concentration beginning at the 1-h timepoint ( Fig. 2 B), indicating suppression of mitochondrial fission.

### 3.3. Oxidative phosphorylation, respiration rate, and mitochondrial coupling are upregulated and enhanced in cells that survive DxR assault

Mitochondrial fusion is associated with energy production via electron transport and oxidative phosphorylation (OXPHOS). To assess if our observation of upregulated MFN-2, along with its mediated fusion, predicted subsequent increases in OXPHOS activity, we probed for subunits of each respiratory chain complex, I–V ( Fig. 3 A). Significant increases were observed for complexes I, III, and IV, with a substantial 10-fold surge occurring for complex V, ATP Synthase. Interestingly, expression for complex II, succinate dehydrogenase, was slightly decreased compared to control.

To determine if the upregulation of mitochondrial fusion and OXPHOS complexes in treated cells accompanied respiration rate changes, we introduced a glutamate/malate respiratory substrate to facilitate electron entry into the ETC via Complex I. Using ADP + glutamate/malate-generated NADH, which facilitates shuttling electrons to Complex I, we observed that mitochondria in treated cells increase state III respiration compared to control ( Fig. 3 B). This corresponded with lower state IV respiration (however not significant) and a statistically significant escalation in the respiratory control ratio (RCR; state III/state IV), indicating increased mitochondrial coupling and more efficient ATP production ( Fig. 3 B).

### 3.4. MFN-2 significantly increases chemoresistance and insensitivity

To deduce the role of MFN-2 in the DxR drug response of Jurkats, we next knocked out its expression through transfection of an MFN-2 KO CRISPR vector. Knockout was validated through western immunoblot (Fig. 4 A). To ensure that there was no compensatory MFN-1 expression to induce unaccounted fusion, we probed for it again, finding little change (data not shown). DxR was administered at 0.50 μM to both wildtype control and MFN-2 knockout cultures for a duration of 24 h. Compared to control, median lethal dose for MFN-2-KO was reduced from 0.81 μM in WT to 0.49 μM in KO, indicating significant sensitization in MFN-2 deficient cells (Fig. 4 B).

### 4. Discussion

DxR is a standard-of-care nonselective anthracycline molecule routinely used in the treatment of leukemia [21]. In this study, we demonstrated that Jurkat leukemia cells, if they are to survive a DxR assault, must quickly change mitochondrial morphology, rates of oxidative phosphorylation, and respiratory capacity. Specifically, we show that mitochondrial fusion mediated by MFN-2 (but not MFN-1), as demonstrated that Jurkat leukemia cells, if they are to survive a DxR assault, must quickly change mitochondrial morphology, rates of oxidative phosphorylation, and respiratory capacity. Specifically, we show that mitochondrial fusion mediated by MFN-2 (but not MFN-1), as well as significant increases in expression for particular OXPHOS respiratory proteins and mitochondrial respiration rate, are required for Jurkat cell survival at median lethal DxR doses. Together these data suggest that mitochondrial dynamics, as well as their associated metabolic programs, play an important role in leukemia responses to DxR chemotherapy, and may also account for subsequent DxR chemoresistance and desensitization.

As a DNA intercalator, DxR inhibits the action of topoisomerase II, generating DNA damage and thus preventing biosynthesis and...
additional cancer growth [22]. Though effective in treating many cancers, its use is limited by several side effects, especially cardiomyopathy [23], which presents a need to maximize its efficacy by reducing its therapeutic dose concentration. At higher concentrations, previous works have linked DxR-induced mitochondrial dysfunction to cardiomyopathy development through decreased respiration of Jurkat cells at 5–10 μM DxR [24]. However, it has been estimated that typical plasma concentrations of DxR in patients is as low as 1–2 μM [25], meaning a gap exists regarding mitochondrial action at smaller clinical concentrations.

Mitochondria possess the capacity to fluctuate between structural morphologies based on cellular stresses, bioenergetic demand [26], and disease state. DRP-1 is activated post-translationally by Cdk1/cyclin B-mediated phosphorylation of Serine-616 [27], translocating to the mitochondrial outer membrane, homo-oligomerizing into a ring structure, and inducing morphological fission [28]. This fission has been observed in several types of cancer [29–31], and studies have found DRP-1 expression to be correlated to mitotic cell cycle phases in which proliferation occurs [32]. In our study, elevated levels of both total and phosphorylated DRP-1 in untreated Jurkats are consistent with this notion, as is the corresponding decreased expression of DRP-1 (Fig. 2) and smaller proportion of G2/M phase cells (Fig. 1) in the DxR treated groups. Conversely MFN-2, which induces outer mitochondrial membrane fusion, was observed to increase in treated cells, and while MFN-1 also increased, it was marginal in comparison (Fig. 2). Additionally, prohibitin protein 1 (PHB-1), which assembles at the mitochondria inner membrane to facilitate mitochondrial fusion and stabilize OXPHOS proteins [33], was found to increase with DxR treatment, particularly at 1 μM (Fig. 2). Together, these data suggest a role for mitochondrial dynamics in Jurkat responses to DxR, and in particular, implicate MFN-2 mediated fusion in insensitivity and survival.

Fused mitochondria are associated with oxidative phosphorylation-driven bioenergetics [34], and while healthy differentiated cells typically employ the OXPHOS metabolic program for energy, it is well known that cancer cells are aerobically glycolytic. Although less efficient at ATP generation per molecule of glucose, this transformation from oxidative metabolism to aerobic glycolysis, observed first by Otto Warburg, permits cancer cells to utilize several of the biosynthetic precursors required to support and sustain rapid proliferation [35]. Our data corroborate this process, with a relatively small amount of OXPHOS respiratory chain proteins in the untreated group. Interestingly, after all DxR treatments, expression of OXPHOS proteins (and especially Complex V), were dramatically increased, with complex II providing the lone exception (Fig. 3A). The reasons for this preferential utilization of NADH and the proton pump faculty of Complex I aren’t clear, though a possible explanation is that FADH2 electron transfer bypasses Complex I [36] to instead feed into Complex II, which doesn’t translocate protons and thus is a less efficient energy production method.

We next assessed the relationship between increased OXPHOS respiratory protein expression and respiration rate (Fig. 3B). In the presence of substrate (for Complex I-driven respiration, glutamate/malate) and inorganic phosphate, mitochondria will consume oxygen. Upon
adding exogenous ADP to the mitochondria in a reaction chamber, oxygen consumption significantly increases, as its coupled to the conversion of ADP into ATP. Assuming saturation of both substrate and ADP, mitochondrial respiration is limited only by the intrinsic activity of the respiratory chain itself, achieving maximal, or state III, respiration [37]. When ADP levels are exhausted and the ATP:ADP ratio is very high, minimal respiratory capacity, or state IV respiration, can be measured; any oxygen consumption in this state corresponds exclusively to proton leak. Using a Clark-type polarographic oxygen electrode, we found that state III respiration was positively correlated to DxR concentration relative to control, corroborating the increased expression of respiratory complexes previously observed through immunoblot. Taken together, we observe a hastened respiratory rate facilitated by increased respiratory complex expression in response to DxR treatment, contrary to prior studies at higher DxR doses. Moreover, the increased RCR in treated cells indicates more efficient ATP production and tighter mitochondrial coupling, suggesting that rather than damage mitochondria of surviving cells, DxR forces maximum efficiency.

Finally, to determine the impact of observed MFN-2 mediated fusion in surviving cells, as well as the increase in OXPHOS, MFN-2 was knocked out using a CRISPR-MFN2-KO vector, the action of which was validated by immunoblot (Fig. 4A and B). A prior study found that while knockout or silencing of both MFN-1 and MFN-2 eliminates mitochondrial fusion, it results in defective cell growth and widespread heterogeneity of mitochondrial membrane potential; greater outcomes were achieved by knocking out only one [38]. Having observed little MFN-1 modulation in response to DxR, MFN-2 was selected to inhibit mitochondrial fusion and OXPHOS, both of which have roles in chemo-resistant cancers [39,40]. Interestingly, when compared to treated wildtype, MFN-2 KO cells demonstrated significant drug sensitization to DxR (Fig. 4B), with a reduced median lethal dose (0.81 µM for treated wildtype, 0.49 µM for treated KO).

Our work here presents MFN-2 and mitochondrial fusion as targets for enhancing doxorubicin efficacy and increasing cell sensitivity to treatment, which with further research may provide opportunities to reduce adverse side effects and improve clinical outcomes. Moreover, our findings further implicate mitochondrial dynamics not only in the bioenergetics of cancer, but in the metabolism of therapies designed to abate its progress.

Author statement

Carl W. Decker: conceptualized, methodology, validation, formal analysis, investigation visualization and writing-original draft. Jerome Garcia: conceptualization, methodology, resources and writing-review and editing. Kristelle Gatchalian: validation, investigation and formal analysis. Daronsha Arceneaux: investigation and validation. Clarice Choi: investigation and validation. Derek Han: resources and writing-review and editing. Jeniffer B. Hernandez: methodology, resources, writing-review and editing, and supervision.

Author contributions

CWD designed the study, performed experiments, and wrote the manuscript. JG performed experiments, analyzed data, and revised the manuscript. KG and CC conducted qPCR experiments. DH revised the manuscript. JH designed the study, analyzed data, revised the manuscript, developed research plan.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We would like to thank Krista Siu and Shireen Qishta for their help running SDS-PAGE, and Michael Bloomfield for help running the oxygen electrode.

References

[1] T. Vos, C. Allen, M. Arewa, R.M. Barber, Z.A. Bhutta, A. Brown, A. Carter, D. C. Casey, F.J. Charlon, A.Z. Chen, M. Coggeshall, L. Cornaby, L. Dandona, D. J. Dicker, T. Dilege, H.E. Erskine, A.J. Ferrari, C. Fitzmaurice, T. Fleming, C.J. L. Murray, Global, and national, and regional, incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015, Lancet 388 (10053) (2016) 1545–1620, https://doi.org/10.1016/S0140-6736(16)31678-6.

[2] H. Wang, M. Naghavi, C. Allen, R.M. Barber, Z.A. Bhutta, A. Carter, D.C. Casey, F.J. Charlon, A.Z. Chen, M. Coggeshall, L. Dandona, D.J. Dicker, H.E. Erskine, A.J. Ferrari, C. Fitzmaurice, K. Foreman, M.H. Forouzanfar, M.S. Fraser, C.J.L. Murray, Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015, Lancet 388 (10053) (2016) 1459–1454, https://doi.org/10.1016/S0140-6736(15)03121-2.

[3] T.P. Whitehead, C. Metayer, J.L. Wimells, A.W. Singer, M.D. Miller, Childhood leukemia and primary prevention, Curr. Probl. Pediatr. Adolesc. Health Care 46 (10) (2016) 317–352, https://doi.org/10.1016/j.cppac.2016.08.004.

[4] P. Cai, J. Hao, D. Wang, J. Xu, Comparative efficacy of different chemotherapies for non-Hodgkin lymphoma: a network-meta-analysis, Oncotarget 8 (53) (2017) 91228–91247, https://doi.org/10.18632/oncotarget.20437.

[5] A.J. Moskowitz, M.A. Lunning, S.M. Horwitz, How I treat the peripheral T-cell lymphomas, Blood 123 (17) (2014) 2636–2644, https://doi.org/10.1182/blood-2013-12-56245.

[6] T. T. Vu, J. Ryan, R. Carrasco, D. Neujord, D.J. Rossi, R.M. Stone, D.J. DeAngelis, M.G. Frattini, A. Letai, Relative mitochondrial priming of myeloblasts and normal HSICs determines chemotherapeutic success in AML, Cell 151 (2) (2012) 344–355, https://doi.org/10.1016/j.cell.2012.08.038.

[7] C.-H. Pui, D. Pei, J.T. Sandlund, D. Campana, R.C. Ribeiro, B.I. Razouk, J. E. Rubnitz, S.C. Howard, N. Hijiya, S. Jeha, C. Cheng, J.R. Downing, W.E. Evans, M.V. Relling, M. Hudson, Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia, J. Clin. Oncol. 23 (31) (2005) 7936–7941, https://doi.org/10.1200/jco.2004.01.0053.

[8] G.K. Rivera, Y. Zhou, M.L. Hancock, A. Gajar, J. Rubnitz, R.C. Ribeiro, J. T. Sandlund, M. Hudson, M. Relling, W.E. Evans, C.H. Pui, Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia, Cancer 103 (2) (2005) 368–376, https://doi.org/10.1002/cncr.20743.

[9] J.M. Chessells, P. Veys, H. Kempski, P. Henley, A. Leiper, D. Webb, I.M. Hann, Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia, Br. J. Haematol. 123 (3) (2003) 396–405, https://doi.org/10.1046/j.1365-2457.2003.04594.x.

[10] Carmela Guido, et al., Mitochondrial fission induces glycolytic reprogramming in cancer-associated myofibroblasts, driving stromal lactate production, and early tumor growth, Oncotarget 3 (8) (Aug 2012) 798–810, https://doi.org/10.18632/oncotarget.574.

[11] Cong-Hui Yao, et al., Mitochondrial fusion supports increased oxidative phosphorylation during cell proliferation, Elife 8 (Jan) (2019), e41351, https://doi.org/10.7554/eLife.41351.

[12] Silva Ramos, Eduardo, et al., Bioenergetic roles of mitochondrial fusion, Biochem. Biophys. Acta Bioenerg. 1857 (8) (Aug 2016) 1277–1283, https://doi.org/10.1016/j.bbabio.2016.04.002.

[13] Jianqin Xie, et al., “Mfn2 ablation causes an oxidative stress response and eventual neuronal death in the Hippocampus and cortex.” Mol. Neurodegener., 13(1), p. 5. DOI.org, doi:10.1186/s13234-018-0238-8.

[14] Pich, Sara, et al., “The charcot-marie-tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through expression of OXPHOS system.” Hum. Mol. Genet., 14(11), p. 1405–1415. DOI, doi:10.1093/hmg/ddh149.

[15] W. Dai, L. Jiang, Dysregulated mitochondrial dynamics and metabolism in obesity, diabetes, and cancer, Front. Endocrinol. 10 (2019), https://doi.org/10.3389/fendo.2019.00057.

[16] J. Zhao, J. Zhang, M. Yu, X. Yie, X. Huang, D.W. Wolff, P.W. Abel, Y. Tu, Mitochondrial dynamics regulates migration and invasion of breast cancer cells, Oncogene 32 (40) (2012) 4814–4824, https://doi.org/10.1038/onc.2012.494.

[17] B. Vaidya, V. Parvathaneni, N.S. Kulkarni, S.K. Shukla, J.K. Damon, A. Sarode, D. Kanabar, J.V. Garcia, S. Mitragotri, A. Muth, V. Gupta, Cyclodextrin modified erlotinib-loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer, Int. J. Biol. Macromol. 122 (2019) 338–347, https://doi.org/10.1016/j.jbiomac.2018.10.181.
C.W. Decker et al.

[18] J. Garcia, C.W. Decker, S.J. Sanchez, J.M. Ouk, K.M. Siu, D. Han, Obesity and steatosis promotes mitochondrial remodeling that enhances respiratory capacity in the liver of ob/ob mice, FEBS (Fed. Eur. Biochem. Soc.) Lett. 592 (6) (2018) 916–927, https://doi.org/10.1016/j.febslet.2018.07.036.

[19] J.B. Hernandez, C. Chang, M. LeBlanc, D. Grimm, J.L. Le Lay, K.H. Kaestner, Y. Zheng, M. Montminy, The CREB/CREC2 pathway modulates autoimmune disease by promoting Th17 differentiation, Nat. Commun. 6 (1) (2015), https://doi.org/10.1038/ncomms8216.

[20] J. Garcia, C.W. Decker, S.J. Sanchez, J.M. Ouk, K.M. Siu, D. Han, Obesity and steatosis promotes mitochondrial remodeling that enhances respiratory capacity in the liver of ob/ob mice, FEBS (Fed. Eur. Biochem. Soc.) Lett. 592 (6) (2018) 916–927, https://doi.org/10.1016/j.febslet.2018.07.036.

[21] C. Guven, Y. Sevgiler, E. Taskin, Mitochondrial dysfunction associated with obesity and insulin resistance, Annu. Rev. Genet. 39 (1) (2005) 503–536, https://doi.org/10.1146/annurev.genet.38.072902.093019.

[22] J. Garcia, C.W. Decker, S.J. Sanchez, J.M. Ouk, K.M. Siu, D. Han, Obesity and insulin resistance, Cell Metabol. 17 (4) (2013) 491–506, https://doi.org/10.1016/j.cmet.2013.03.002.

[23] Y. Octavia, C.G. Tocchetti, K.L. Gabrielson, S. Janssens, H.J. Crijns, A.L. Moens, J.L. Nitiss, Targeting DNA topoisomerase II in cancer chemotherapy, Nat. Rev. Cancer 18 (10) (2018) 590–598, https://doi.org/10.1038/s41560-018-0165-8.

[24] Z. Tao, H.G. Withers, H.S. Penefsky, J. Goodisman, A.-K. Souid, Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer, Faseb. J. 26 (5) (2012) 2175–2186, https://doi.org/10.1096/fj.11-196542.

[25] M. Tokarska-Schlattner, M. Zang, C. Zupping, T. Wallimann, U. Schlattner, New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics, J. Mol. Cell. Cardiol. 41 (3) (2006) 389–405, https://doi.org/10.1016/j.yjmcc.2006.06.009.

[26] M. Liesa, O.S. Shirihai, Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure, Cell Metabol. 17 (4) (2013) 491–506, https://doi.org/10.1016/j.cmet.2013.03.002.

[27] H. Otera, N. Ishihara, K. Mihara, New insights into the function and regulation of mitochondrial fission, Biochim. Biophys. Acta Mol. Cell Res. 1833 (5) (2013) 536–550, https://doi.org/10.1016/j.bbamcr.2013.02.002.

[28] K. Okamoto, J.M. Shaw, Mitochondrial morphology and dynamics in yeast and multicellular eukaryotes, Annu. Rev. Genet. 39 (1) (2005) 503–536, https://doi.org/10.1146/annurev.genet.38.072902.090319.

[29] J. Rehman, H.J. Zhang, P.T. Toth, Y. Zhang, G. Marsboom, Z. Hong, R. Salgia, A.N. Husain, C. Wietkolt, S.L. Archer, Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer, Faseb. J. 26 (5) (2012) 2175–2186, https://doi.org/10.1096/fj.11-196542.

[30] J. Zhao, J. Zhang, M. Yu, Y. Xie, Y. Huang, D.W. Wolff, P.W. Abel, Y. Tu, Mitochondrial dynamics regulates migration and invasion of breast cancer cells, Oncogene 32 (40) (2013) 4814–4824, https://doi.org/10.1038/onc.2012.494.

[31] A. Ferreira-da-Silva, C. Valacca, R. Reihl, H. Populo, P. Soares, M. Sobeihn-Simões, L. Scorrano, V. Mâximo, S. Campello, Mitochondrial dynamics protein Drp1 is overexpressed in oncocytic thyroid tumors and regulates cancer cell migration, PloS One 10 (3) (2015), e0122308, https://doi.org/10.1371/journal.pone.0122308.

[32] Deepak Kumar Tanwar, et al., CROSSTALK BETWEEN THE MITOCHONDRIAL FUSION PROTEIN, Drp1, AND THE CELL CYCLE IS IDENTIFIED ACROSS VARIOUS CANCER TYPES AND CAN IMPACT SURVIVAL OF EPITHELIAL OVARIAN CANCER PATIENTS, Oncotarget 7 (37) (Sept. 2016) 60021, https://doi.org/10.18632/oncotarget.11047.

[33] A. Signorile, G. Sgramma, F. Bellomo, D. De Raso, Prohibin1: a critical role in mitochondrial functions and implication in diseases, Cells 8 (1) (2019) 71, https://doi.org/10.3390/cells8010071.

[34] M.G. Vander Heiden, L.C. Cantley, C.B. Thompson, Understanding the Warburg effect: the metabolic requirements of cell proliferation, Science 324 (5930) (2009) 1029–1033, https://doi.org/10.1126/science.1160809.

[35] H. Lodish, A. Berk, S.L. Zipursky, et al., Section 16.2, electron transport and oxidative phosphorylation. Molecular Cell Biology, fourth ed., W. H. Freeman, New York, 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK21528/.

[36] M.D. Brand, D.G. Nicholls, Assessing mitochondrial dysfunction in cells, Biochem. J. 435 (2) (2011) 297–312, https://doi.org/10.1042/bj20110162.

[37] H. Chen, A. Chomyn, D.C. Chan, Disruption of fusion results in mitochondrial heterogeneity and dysfunction, J. Biol. Chem. 280 (28) (2005) 26185–26192, https://doi.org/10.1074/jbc.m503062200.

[38] C. Kingnate, K. Charoenkwan, S. Kumfu, N. Chattipakorn, S.C. Chattipakorn, Prohibitins: a critical role in mitochondrial fission, Mol. Cells 28 (4) (2009) 1058–1064, https://doi.org/10.1007/s10059-009-0105-2.

[39] C. Kingnate, K. Charoenkwan, S. Kumfu, N. Chattipakorn, S.C. Chattipakorn, Possible roles of mitochondrial dynamics and the effects of pharmacological interventions in chemoresistant ovarian cancer, EliBioMedicine 34 (2018) 256–266, https://doi.org/10.1016/j.ebion.2018.07.026.

[40] K. Lee, J.M. Giltnane, J.M. Balko, L.J. Schwarz, A.L. Guerrero-Zotano, K.E. Hutchinson, C.L. Arteaga, MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation, Cell Metabol. 26 (4) (2017) 633–647, https://doi.org/10.1016/j.cmet.2017.09.009, e7.